市场概况

The global Alzheimer’s disease therapeutics market was valued at USD 3.52 十亿 2022 预计将达到美元 6.66 十亿 2029, 年复合增长率为 9.2% 从 2023 到 2029. Increasing prevalence of Alzheimer’s disease worldwide and investments in therapeutic development are driving market growth. Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. Current treatments provide temporary symptom improvement, but there is a need for effective pharmacological approaches. Laboratory tests and brain-imaging technologies aid in diagnosis. The market primarily consists of symptomatic treatments, with seven approved medications. Clinical trials are in progress, with a focus on Phase II development. The approval of Aducanumab in 2021 and the introduction of novel therapies will contribute to market growth. The market is driven by the rising prevalence of Alzheimer’s disease and significant R&D investments.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global therapeutics of Alzheimer’s disease market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

市场根据多种因素进行细分, 包括毒品类, 性别, 年龄阶层, severity, 和地理.
毒品类: ACE inhibitors, NMDA inhibitors, 其他的
性别: 男人, 女性
年龄阶层: 65-74 年, 75-84 年, 85 年 & 多于
Severity type: mild, moderate, severe
地理: 北美, 欧洲, 亚太地区

ACE inhibitors are projected to have a significant share in the global Alzheimer’s disease therapeutics market, but the fastest-growing segment is expected to be other classes of drugs. The recent approval of biologics like Aducanumab (Aduhelm) is anticipated to drive the global Alzheimer’s disease therapeutics market in the future. In terms of gender, women are expected to contribute significantly due to their longer life expectancy and larger population affected by Alzheimer’s disease. Among different age groups, those aged 85 years and above are expected to dominate the market, but the fastest-growing segment will be the population aged 65 years and above. Individuals with mild forms of the disease will hold a significant share in the global therapeutics market, while the fastest-growing segment will be individuals with moderate forms.

In the U.S., the incidence of Alzheimer’s disease was reported to be 229,385 在 2021, and this number is predicted to increase substantially. The United States holds a dominant position in the global market due to factors such as affordability of healthcare, knowledge and awareness, and technological advancements. 然而, China is expected to experience faster growth with a high compound annual growth rate (复合年增长率) due to the rising geriatric population, increased awareness, and growing healthcare expenditure in the Asia-Pacific (亚太地区) 地区.

竞争格局

The Alzheimer’s Disease (AD) market is primarily dominated by symptomatic treatments, with seven approved medications available. Leading players in the global market include AbbVie Inc, Alzamend Neuro, 公司, Alzinova AB, Asceneuron SA, Biogen Inc, Biohaven, 有限公司, BioVie Inc., Denali Therapeutics Inc., Eisai Co., 有限公司, 伊利礼来公司, GreenValley Inc., 约翰逊 & 约翰逊, KeifeRx, 有限责任公司, NeuroKine Therapeutics LLC, 诺华公司, UCB SA, Vaccinex Inc, 除其他外. These companies employ strategies such as collaborations, 收购, geographical expansion, research and development investments, and the development of novel drugs to compete in the market.

最新行业发展

Biogen announced in April 2022 that the European Medicines Agency (EMA) withdrew the Marketing Authorization Application (MAA) for aducanumab due to insufficient data.

In March 2022, Corium, 公司. received FDA approval for Adlarity as a treatment for Alzheimer’s disease patients with mild, moderate, or severe dementia.

In June 2021, Biogen obtained accelerated FDA approval for Aduhelm based on the results of Phase 3 临床试验 (EMERGE and ENGAGE) conducted on patients with early-stage Alzheimer’s disease and confirmed amyloid pathology.

报告范围

To analyze and forecast the market size of the global therapeutics of Alzheimer’s disease market.
To classify and forecast the global therapeutics of Alzheimer’s disease market based on drug class, 性别, 年龄阶层, severity type, 地理.
To identify drivers and challenges for the global therapeutics of Alzheimer’s disease market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global therapeutics of Alzheimer’s disease market.
To identify and analyze the profile of leading players operating in the global therapeutics of Alzheimer’s disease market.

为什么选择这份报告

Gain a reliable outlook of the global therapeutics of Alzheimer’s disease market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.